Richard Ferrari

Bio

Mr. Ferrari is a Co-Founder of De Novo Ventures which has $650 million under management and which is one of the premier firms dedicated to Medical Devices and Bio-Technology. Additionally, Rich has been a successful CEO of two publicly traded medical technology companies. Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters which was eventually acquired for $125 million by Boston Scientific. His most recent success, CardioThoracic Systems (CTS), the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, was acquired by Guidant for $350 million in November 1999. Rich was a co-founder of CTS and the force that led the company to an initial public offering in only 7 months, the fastest of any medical technology company in history. Mr. Ferrari also Co-Founded the Medical Technology Group which spun-out Integrated Vascular Systems, acquired by Abbot Vascular and Ensure, acquired by J&J. Mr. Ferrari also serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum, as well as a board member for the Stanford | Coulter Foundation for Translational Medicine. Previously Mr. Ferrari held the positions of Executive Vice President and General Manager of ADAC Laboratories. In 1996 he founded Saratoga Ventures, a venture capital partnership that has provided seed financing to startup medical technology companies. Mr. Ferrari is the recipient of the Mallinckrodt Award for Excellence in Medicine and has been a finalist for the Entrepreneur of the Year Award. Rich holds a BS degree from Ashland University and an MBA from the University of South Florida.